Showing results (1671-1680 of 4,521) with videos related to

Sort By:
Pageof 453
Future Oncology (London, England)|May 19, 2025
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in ItalyPhilipp Ivanyi, Ash Bullement, Andrea Botticelli, et al.
Future Oncology (London, England)|May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myelomaSagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Future Oncology (London, England)|May 12, 2025
'Perspectives of pulmonologists and thoracic surgeons on Oligometastatic disease: curability, treatment approaches, and disease trajectory'Damla Azaklı, Inanc Yazici, Aysegul Erinc, et al.
Future Oncology (London, England)|May 8, 2025
A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS)Hiroyuki Kodama, Yukiya Narita, Michio Nakamura, et al.
Future Oncology (London, England)|May 9, 2025
Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to accessJesús Garcia-Foncillas, Arnaud Bayle, Dirk Arnold, et al.
Future Oncology (London, England)|May 5, 2025
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patientsFrançois Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, et al.
Future Oncology (London, England)|April 1, 2025
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patientsRana R McKay, Ashley E Ross, Mark A Preston, et al.
Future Oncology (London, England)|March 27, 2025
Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK studyNeal D Shore, Henry H Woo
Future Oncology (London, England)|March 25, 2025
Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK studyNeal D Shore, Henry H Woo
Future Oncology (London, England)|November 14, 2025
Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial ProtocolJacqueline V Aredo, Nir Peled, Edurne Arriola, et al.
Pageof 453